Entero Healthcare aims to complete seven acquisitions as part of its strategy to reach a $136 million milestone in the medical technology sector.

Entero Healthcare significantly boosted its revenue by 31.5% in the recent fiscal year, with an EBITDA margin of 4.0%. The company's operating cash flow reached INR 96.2 Cr, and they anticipate their MedTech sector to surpass INR 1000 Cr in the coming fiscal year (FY27).

Entero Healthcare has announced the approval of their Q4 FY26 results, which also included the reappointment of three directors for a five-year term. Simultaneously, they exercised 7,240 stock options and granted an additional 7,300 options. The announcement also highlighted several significant transactions involving multiple subsidiaries.

Entero Healthcare announces a profit of ₹268.8 million for the fiscal year 2026, also approving ESOP allotment. The company has reappointed three directors and completed the acquisition of Vishal Surgicals. Shareholders' Annual General Meeting is scheduled for August 19, 2026.

Entero Healthcare posted a significant 43% year-over-year increase in quarterly sales, reaching INR 19,099.3 million for Q4. This strong growth suggests a robust performance for the company.

Entero Healthcare's Q4 net profit saw a notable increase, reaching ₹280 million compared to last year, indicating strong financial performance. Moreover, revenue surged by approximately ₹5.6 billion year-over-year, signaling robust growth in the company's business operations.

Entero Healthcare Solutions began trading with a 2% price reduction from its initial public offering (IPO). The Securities and Exchange Board of India (SEBI) has given the green light for four companies to proceed with their planned IPOs.

Entero Healthcare Solutions is merging Chethana Pharma Distributors, CPD Pharma, and Rada Medisolutions to improve operational efficiency, cut costs, and streamline their organizational structure, with the changes taking effect on April 15, 2025.